

# Artificial Intelligence in Pharmaceutical Research and Development: A Decade of Advancement, Pitfalls, and Future Prospects

<sup>1</sup>Raj Kumar Devarakonda and \*Rakam Gopi Krishna<sup>2</sup>

<sup>1</sup>Fortrea Inc, 8 Moore Dr, Durham NC 27703

<sup>\*2</sup>Department of Pharmaceutical Chemistry, Marri Laxman Reddy Institute of Pharmacy, Dundigal (V&M), Hyderabad, Telangana, India-500043.

\*Corresponding author: Dr. Rakam Gopi Krishna

Date of Submission: 15-02-2026

Date of Acceptance: 28-02-2026

## Abstract

Artificial intelligence (AI) is transforming medication research and development, giving clinicians new treatment options. Over the past 30 years, machine learning, deep learning, and neural networks have revolutionized drug design, target identification, and clinical trial predictions. AI has boosted pharmaceutical R&D (research and development) by identifying new therapeutic targets, improving chemical designs, and predicting complicated protein structures. Furthermore, generative AI is accelerating the development and re-engineering of medicinal molecules to cater to both common and rare diseases. The integration of artificial intelligence into the pharmaceutical industry has led to significant transformation in the process of drug discovery and development and management of the pharmaceutical sector. Artificial intelligence has accelerated the process of drug discovery by several folds owing to its ability to analyse large datasets and predict drug-target(receptor) interactions, which effectively reduces the time and expenditure. AI enables clinical trial design and patient recruitment through predictive analytics during the trial. It also allows for real-time tracking of patient outcomes and predicts the effectiveness of a trial. Artificial intelligence-driven automation also assists in manufacturing and supply chain processes, enabling inventory optimization and predictive maintenance and thereby improving the productivity as well as affordability of these processes. The current review discusses various key applications, prospects, and challenges of AI in the pharmaceutical industry, focusing on its transformative potential while addressing the need for ethical and regulatory frameworks to ensure equitable and safe AI adoption. AI aims to solve problems, understand and use knowledge, plan, continuously learn, interact socially, promote creativity, and work well with

people. AI has many advantages, such as reduced errors and technological advancements, but also disadvantages, such as high costs and possible job losses. AI is increasingly integrated into the pharmaceutical industry. Partnerships between pharmaceutical companies and AI technology providers can help improve drug discovery, streamline clinical trials.

**Keywords:** Artificial intelligence, Adoption, Identification, Pharmaceutical, Transformative

## I. Introduction

Artificial intelligence (AI) is receiving increasing attention from major pharmaceutical and biotechnology companies worldwide as an engine for new drug development. With three main elements: vast datasets, complex mathematical models, and advanced computational algorithms, AI is a breakthrough in drug discovery and development, bringing new power to the R&D (research and development) of new drugs. Approximately 80% of pharmaceutical and life sciences researchers use AI to accelerate or support their drug discovery efforts.<sup>1</sup> The development of artificial intelligence (AI) is changing the drug discovery, development, and management paradigm in the pharmaceutical industry. Thus far, drug discovery and development have been conventionally long and expensive processes that have taken as long as 10-15 years, and billions of dollars need to be spent for one molecule to come to the market.<sup>2</sup> Artificial intelligence has emerged as a powerful tool that can steer this process by streamlining each stage, including drug discovery and clinical trials, manufacturing, and even supply chain management. Its ability to analyse big data and find patterns to offer efficient and precise predictions points towards even more innovations in the. AI-based technologies, which include machine

learning, natural language processing, and deep learning, are being applied to address the critical issues in pharmaceuticals. For instance, artificial intelligence-based drug discovery platforms accelerate the identification of likely candidates by modelling complex systems of biology and estimating the drug–target interactions with greater precision.<sup>3</sup> Further, AI is making clinical trials faster and more efficient by streamlining the processes of recruitment, trial design, and real-time monitoring, thereby shortening the cycles of drug development while cutting costs. It refers to the creation of systems that can perform tasks that typically require human intelligence, such as problem solving, pattern recognition, and decision-making.

In the pharmaceutical manufacturing field, AI holds potential for revolutionizing processes through predictive maintenance, process automation, and quality control, and it is used in the supply chain management that optimizes logistics, predicts demand, and manages inventory effectively. Improving patients' results using AI is the second focus area. AI, upon analysing the genetic and clinical data, tailors the treatments to individual patients, hence increasing the efficacy and decreasing the adverse effects.<sup>4</sup> Although AI adoption has significant advantages, it faces certain challenges in the pharmaceutical sector. While many positive outcomes have resulted from AI integration in this sector, there are always challenges that accompany these advancements. Critical areas that need to be addressed to fully realize the potential of AI include data privacy issues, issues with bias in algorithms, and regulatory frameworks governing AI-driven processes. However, the combinations of breakthroughs in quantum computing may open new avenues by which AI would become significantly more powerful and beneficial to drug discovery and development activities.<sup>5</sup> This article will delve deep into the influence of AI on the pharmaceutical industry, from discovery through phases of development, manufacturing, and personalized medicine with regard to the ways and mechanisms through which such impacts may differ at various levels. Most probably, it will discuss the challenges and ethical considerations when AI is embraced and look forward to future developments in the succeeding decades that will shape the industry.<sup>6</sup>

### The Emergence and Evolution of AI in Drug Development

At the Dartmouth Conference in 1956, computer scientists proposed a new type of computer for intelligence, giving birth to the

concept of AI, which refers to the intelligence manifested by machines made by humans and is a new technical science that studies and develops theories, methods, technologies, and applied systems to simulate, extend, and augment human intelligence.<sup>7</sup> AI has been developed for over 60 years and has successfully moved from theoretical technology to industrial application, leading the way in industry, agriculture, healthcare, finance, etc.<sup>8</sup>

### Artificial Intelligence in Drug Development: Redefining the Therapeutic Landscape

The pharmaceutical industry has enormous and growing amounts of data, and in terms of models, the best AI pharma model is not to build pure AI processes. Combining humans and AI is often superior to human processes or AI processes alone. Just as in chess, the combination of a human and a computer algorithm can usually beat a human or a computer algorithm alone. AI technology methods need to be sorted out and developed. AI's attention, exploration, and application trials in all sectors of society will inevitably accelerate the maturation and innovation of AI technology methods. When the logic of the "large data → more accurate models → better drugs → more and better data" cycle matures in practice, AI pharma will be significantly accelerated.<sup>9</sup>

### How AI works?

AI works by artificial neural networks (ANNs), machine learning (ML) and deep learning (DL) methods through data analysis, learning and application. Text, graphics, sound, and other data types that can be encoded can all be included in the input data format. Inspired by the networks of biological neurons, an artificial neural network (ANN) is a computational model in which inputs are converted into output values by the neurons.<sup>10</sup> Even in a complicated, noisy, and highly nonlinear environment, the ANN can learn and self-correct. The ANN is commonly used in scenarios where the dataset is extensive and cannot be addressed using linear functions. Multilayers are structured as concealed layers of neurons that have a diverse range of neuron counts. Input variables are chosen from the existing information (for example, drug discovery and drug parameters) such as concentration, compounds, and ligands, and are refined through several training stages to achieve the output. The anticipated value is examined and contrasted with the known value. The disparity between predicted and actual values is traced back

until the difference is minimal to obtain the estimated drug values. This is an extremely intricate simultaneous procedure. Thus, ANN is a computational or mathematical model that relies on a machine learning (ML) technique.<sup>11</sup>

### **Artificial Intelligence in Drug Discovery: Applications and Impact**

The discovery of drugs is typically slow and costly, taking years and vast amounts of resources before there is a glimmer of hope in the form of an identified candidate that might make it to clinical trials. With AI, one could, in theory shave years off timelines, reduce costs, and give drug candidates a better chance of success. AI can handle massive data to predict how chemical compounds could interact and work to model biological systems, which positions it to change the drug-discovery game.<sup>12</sup>

### **Integrating AI into Drug Development and Clinical Trial Design**

Since its inception AI has been readily studied for its ability to enhance the conduction of clinical trials, and certain modifications to the current AI models can make them more compatible with clinical trials.<sup>13</sup>

### **Transforming Pharmaceutical Manufacturing Through Artificial Intelligence**

Manufacturing in the pharmaceutical industry is highly regulated for quality, safety, and efficiency. AI's role in manufacturing revolves around improving predictive maintenance, process optimization, and quality control.<sup>14</sup> The aim here is predictive maintenance:

#### **Predictive maintenance.**

Traditionally, maintenance has been fairly reactive, which means that equipment was typically only repaired after it had broken down. As you can expect, this can sometimes lead to a halt in production. AI shifts the model to proactive for this reason. With the ML algorithms analysing real-time data from machinery sensors, companies can predict when equipment will likely fail, thereby replacing and repairing parts in time to avoid failure, hence minimizing downtime, improving overall equipment effectiveness, and ensuring smooth production flows.<sup>15</sup>

#### **Optimization of processes.**

AI will optimize the production processes of pharmaceuticals that are complex, including

chemical synthesis and formulation. AI models such as reinforcement learning and neural networks can control in real time the factors of manufacturing to ensure consistent quality of products and maximize yields. The technology can also be used to simulate different manufacturing scenarios, an aid to a company in choosing the most efficient process in the reduction of production timelines.<sup>16</sup>

#### **Quality control.**

The drug product must be of quality as well as safety. AI improves the quality control by monitoring data coming from the production line and flags deviation in standard parameter values. Machine learning models thus get trained to identify anomalies or defects in chemical, physical or physical presentation/packaging of the drug, and hence, corrective action is undertaken in real time. AI further reduces the chances of human error, the biggest risk factor in the quality check which is manually carried out.<sup>17</sup>

### **Significant Developments Over the Last Decade**

#### **• Target discovery & design**

AI models can scan vast chemical and biological datasets to pinpoint novel drug targets fast—a process that previously took years.<sup>18</sup>

#### **• Molecular optimization & screening**

Deep learning and generative models can design and refine molecules with desired properties, reducing trial-and-error.

#### **• Clinical trials**

AI has begun transforming trial design, patient recruitment, and data analysis — addressing bottlenecks that once slowed pharmaceutical R&D.<sup>19</sup>

#### **• Manufacturing & quality control**

Machine learning improves process monitoring, predictive maintenance, and analytic assessments in drug production.

#### **• Regulatory adaptation**

Regulators like the FDA are pioneering AI-specific pathways to evaluate digital systems and predictive tools.<sup>20</sup>

### **From Research to Reality: Impact and Emerging Prospects**

#### **Industry Adoption**

• AI-designed therapeutics are progressing to clinical trials with *higher early success rates* compared to traditional methods, suggesting real-world utility beyond theory.<sup>21</sup>

### Commercial collaborations

- Partnerships between AI biotech firms and large pharma companies are expanding rapidly, leveraging generative AI to *drastically accelerate molecular design*. For example, a major collaboration between Nabla Bio and Takeda aims to streamline protein therapeutic design timelines.
- **From Algorithm to Approval: Successful AI-Discovered Drugs**
- Takeda's **AI-crafted psoriasis pill** has succeeded in late-stage trials and is likely to seek regulatory approval a concrete milestone for AI-driven drug design.<sup>22</sup>
- **Integrating Generative AI into R&D Workflows**
- Generative AI (GenAI) is poised to automate documentation, data analysis, trial design and even regulatory submissions enabling faster evidence generation and decision-making.

### Emerging Trends and Strategic Opportunities

#### • Personalized medicine

AI's growing use in integrating genomic, clinical, and lifestyle data paves the way for individualized treatment strategies.<sup>23</sup>

#### • Explainable AI

Developing transparent AI models will be essential to bridge the gap between predictive power and regulatory/clinical trust.

#### • Decentralized trials & digital twins

AI-enabled simulations and digital patient models may revolutionize how trials are conducted, offering quicker, cost-effective paths to approval.

### Artificial Intelligence (AI), Machine Learning (ML), and Deep Learning (DL)

In the CASP14 competition 2020, DeepMind's AlphaFold2 announced a groundbreaking breakthrough in protein structure prediction with a score well ahead of second place. Due to the overwhelming media coverage, they used the terms AI, machine learning, or deep learning to describe this technology.<sup>3</sup> AI includes machine/computer vision and natural language processing (NLP) agents that can perceive the environment and then react to it to obtain a specific goal. The basic idea is to "train" machines using algorithms and data so that they learn how to perform tasks to make inferences or predictions about how things will turn out. The industry tends to use two different groupings to illustrate the concept of machine learning, either by grouping algorithms according to learning scenarios or by grouping algorithms according to their form or

function.<sup>5</sup> Deep learning is an advanced type of machine learning.<sup>24</sup>

Researchers can find disease-related targets and forecast how they will interact with possible treatment candidates thanks to artificial intelligence (AI) algorithms that evaluate a variety of biological data, such as proteomics and genomics. Predictions made possible by AI algorithms offer a more focused and effective approach to drug discovery, which raises the likelihood of a successful drug approval in a shorter amount of time. More medications may be approved and released onto the market as a result of AI algorithms. Optimize the R&D process to cut down on development time and expenditures. This can lower expenses and decrease a drug's time to market. All things considered, though, automation always has expenses, which can now be decreased. The medication development process is also made more efficient by AI models, which enable researchers and pharmaceutical corporations to rank drug candidates according to anticipated metabolic and excretion profiles. To put it another way, this can be stated to lower expenses and shorten the time to market. This explains the market's intense interest in AI, conversational GPT, and machine learning. One important area that is essential to preserving lives is the pharmaceutical business. Given this, pharmacovigilance and the pharmaceutical sector will not be completely overtaken by AI.<sup>25</sup>

## II. Conclusion

This future of AI in the pharmaceutical industry is full of potential changes that will reshape many aspects of developing a drug, conducting clinical trials of that drug, its manufacturing, and the care that comes after. Growth in AI technologies will bring further discoveries in quantum computing, reinforcement learning, and personalized medicine. The most notable development area will be the incorporation of quantum computers into drug discovery. Quantum computers will enable an AI algorithm to execute complex molecular simulations at an unprecedented speed and accuracy that a classical computer could not, solving certain problems in oncology and neurodegenerative diseases. AI applications in personalized medicine will expand further with the use of multi-omics data to predict specific responses by patients to personalized therapies.

## References

- [1]. Varol D. AI in pharma: innovations and challenges | Scilife. Scilife,

- <https://www.scilife.io/blog/ai-pharma-innovation-challenges> (accessed 18 February 2025).
- [2]. Tripathi N, Goshisht MK, Sahu SK, et al. Applications of artificial intelligence to drug design and discovery in the big data era: a comprehensive review. *Mol Divers* 2021; 25(3): 1643–1664.
- [3]. Hur JY.  $\gamma$ -Secretase in Alzheimer's disease. *Exp Mol Med* 2022; 54(4): 433–446.
- [4]. Simes DC, Viegas CSB, Araújo N, et al. Vitamin K as a diet supplement with impact in human health: current evidence in age-related diseases. *Nutrients* 2020; 12(1): 138.
- [5]. Perrone MG and Scilimati A.  $\beta$ (3)-Adrenoceptor ligand development history through patent review. *Expert Opin Ther Pat* 2011; 21(4): 505–536.
- [6]. Hennig M and Hennig M. Artificial intelligence in pharmaceutical technology and drug delivery design. *Pharma Excipients*, <https://www.pharmaexcipients.com/news/artificial-intelligencepharmaceutical> (2024, accessed 18 February 2025).
- [7]. Label Your Data. How is AI in drug discovery changing the pharmaceutical industry? Label Your Data. <https://labeyourdata.com/articles/ai-in-drugdiscovery> (2024, accessed 18 February 2025).
- [8]. Patel J, Patel D, Meshram D. Artificial Intelligence in Pharma Industry-A Rising Concept. *Journal of Advancement in Pharmacognosy*. 2021; 1(2).
- [9]. Rakam Gopi Krishna, Satya Lahari Boddu, Samhitha Damera, Akash Kumar Kadapa, Krishna Mohan Reddy Dharmareddy and Charithaa Katha. Advances in Anti-Tubercular Agents: A Comprehensive Review. *Biomedical & Pharmacology Journal*. 2025;18(1):547-558.
- [10]. Kuchi Manjeera, Rakam Gopi Krishna, V.A.N.V. Harita, Suvendu Saha, Ch. Sandeep Reddy. Preliminary Phytochemical Screening and Antibacterial Activity of *Anthocephalus cadamba* Whole Plant. *Vignan's Journal of Biotechnology and Pharmacy*. 2025; 1(1): 8-14.
- [11]. Rakam Gopi Krishna, Kadagoni Pravalika, Ramesh Konda, V A N V Harita, G. Haritha. Analytical Method Development and Validation of Remdesivir and Griseofulvin in API and its Dosage Form by RP-HPLC. *International Journal of Drug Delivery Technology*. 2025;15(1):139-45. doi: 10.25258/ijddt.15.1.19
- [12]. Krishna RG, Nausheen A, Shivani BG, Kingari R, Pallavi K, Saha S. Extraction, Investigation of Phytochemical Composition, and *In Vitro* Antioxidant Activity of *Indigofera cordifolia*. *J. Pharma. QAQC*.2025 August 02; 7(2): 27-36.
- [13]. Vora LK, Gholap AD, Jetha K, Thakur RR, Solanki HK, Chavda VP. Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. *Pharmaceutics*. 2023 Jul 10;15(7):1916.
- [14]. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. *Drug discovery today*. 2021 Jan;26(1):80.
- [15]. Yang F, Zhang Q, Ji X, Zhang Y, Li W, Peng S, Xue F. Machine learning applications in drug repurposing. *Interdisciplinary Sciences: Computational Life Sciences*. 2022 Mar;14(1):15-21.
- [16]. Quazi S. Role of artificial intelligence and machine learning in bioinformatics: Drug discovery and drug repurposing. [Preprint]. 2021.
- [17]. Selvaraj C, Chandra I, Singh SK. Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries. *Molecular diversity*. 2021 Oct 23:1-21.
- [18]. Rakam Gopi Krishna, M. Srinivasa Murthy, V. Kavya. Method development and validation of RP-HPLC method for the determination of Sumatriptan in Bulk and Pharmaceutical Dosage form. *Research Journal of Pharmacy and Technology*. 2021;14(11): 5856-2.
- [19]. Gopi Krishna Rakam, Raja Sundararajan. *In vitro* antioxidant activity of *Bougainvillea glabra* and *Mucunapruriens*. *International Journal of Research in Pharmaceutical Sciences*. 2020;11(1): 806-812.
- [20]. Rakam Gopi Krishna and Raja Sundararajan. Screening of antioxidant activity of *Mucuna pruriens* by *in vivo* model. *International Journal of Research in Pharmaceutical Sciences*. 2018; 10(1): 523-530.
- [21]. Makne PD, Sontakke SS, Lakade RD, Tompe AS, Patil SS. Artificial Intelligence: A Review. *World Journal of Pharmaceutical Research*. 2015; 12:739.



- [22]. Khanna V, Ahuja R, Popli H. Role of artificial intelligence in pharmaceutical marketing: a comprehensive review. *Journal of Advanced Scientific Research*. 2020 Aug 10;11(03):54-61.
- [23]. Kuchi Manjeera and Raja Sundararajan. Toxicity Studies of *Abutilon crispum* and *Indigofera prostrata* Whole Plants on Wistar Rats. *Tropical journal of Natural Product Research*. 2024; 8(11): 9073-9078.
- [24]. KuchiManjeeraandRajaSundararajan. StandardizationandPhytochemicalscreeningof *Abutiloncrispum*. *ResearchJournalofPharmacyandTechnology*. 2024; 17(4):1621-1630.
- [25]. KuchiManjeeraandRajaSundararajan. EvaluationofAntidiabeticActivityof *Indigofera prostrata* on Normal and Streptozotocin Induced Diabetic Albino Wistar Rats. *Journal of Natural Remedies*. 2024; 24(10):2217-2230.